Structural basis of anti-SARS-CoV-2 activity of hydroxychloroquine: specific binding to NTD/CTD and disruption of LLPS of N protein

Source: bioRxiv.org

Mei Dang, Jianxing Song

doi: https://doi.org/10.1101/2021.03.16.435741

Abstract

SARS-CoV-2 is the coronavirus causing the catastrophic pandemic which already led to >120 millions of infections and >2.6 millions of deaths.

Hydroxychloroquine (HCQ) has been shown to own promising potential in clinically combating SARS-CoV-2 but the underlying mechanisms still remain almost unknown. So far, all action sites are proposed on the host cells, and in particular no specific viral target protein has been experimentally identified.

In this study, by use of DIC microscopy and NMR spectroscopy, for the first time we have decoded that HCQ specifically binds to both N-terminal domain (NTD) and C-terminal domain (CTD) of SARS-CoV-2 nucleocapsid (N) protein to inhibit their interactions with nucleic acids (NAs), as well as to disrupt its NA-induced liquid-liquid phase separation (LLPS) essential for the viral life cycle including the package of gRNA and N protein into new virions.

These results suggest that HCQ may achieve its anti-SARS-CoV-2 activity by interfering in several key steps of the viral life cycle.

The study not only provides a structural basis for the anti-SARS-CoV-2 activity of HCQ, but also indicates that SARS-CoV-2 N protein and its LLPS represent key targets for further optimization and development of anti-SARS-CoV-2 drugs.

Competing Interest Statement

The authors have declared no competing interest.

Please read the full study here: Structural-basis-of-anti-SARS-CoV-2-activity-of-hydroxychloroquine-specific-binding-to-NTDCTD-and-disruption-of-LLPS-of-N-protein.pdf

Related: Act early with early Covid-19 treatment: Dr Vladimir Zelenko

 COVID-19 outpatients – early risk-stratified treatment with zinc plus low dose hydroxychloroquine and azithromycin: a retrospective case series study

The story behind hydroxychloroquine and the Zelenko Protocol: safe pre-hospital treatments for Covid

‘Only a one in 17 billion chance hydroxychloroquine doesn’t work’: medical professor

Low Dose Hydroxychloroquine is Associated with Lower Mortality in COVID-19: A Meta-Analysis of 27 Studies and 44,684 Patients

Top US medics recommend ‘sequenced multidrug therapy’ including HCQ & Ivermectin, for early high-risk COVID-19 infections

Epidemiologist At Yale Provides Testimony On Hydroxychloroquine For Treating COVID-19

The AMA Quietly Admits They Lied About Hydroxychloroquine